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Abstract
Human-tropic porcine endogenous retroviruses (PERV) such as PERV-A and PERV-B can infect human cells and are therefore a
potential risk to recipients of xenotransplants. A similar risk is posed by recombinant viruses containing the receptor-binding site of PERV-A
and large parts of the genome of the ecotropic PERV-C including its long terminal repeat (LTR). We describe here the unique organization
of the PERV-C LTR and its changes during serial passage of recombinant virus in human cells. An increase in virus titer correlated with
an increase in LTR length, caused by multiplication of 37-bp repeats containing nuclear factor Y binding sites. Luciferase dual reporter
assays revealed a correlation between the number of repeats and the extent of expression. No alterations have been observed in the
receptor-binding site, indicating that the increased titer is due to the changes in the LTR. These data indicate that recombinant PERVs
generated during infection of human cells can adapt and subsequently replicate with greater efficiency.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Porcine endogenous retroviruses (PERVs) pose a poten-
tially major risk during xenotransplantation. This new tech-
nology, the transplantation of cells, tissues, or organs from
animals to humans, has been developed to overcome the
severe lack of human transplants. Among all suitable animal
species, pigs are for several reasons the most favored. The
advantages of pigs as donors include their similar physiol-
ogy, an unlimited availability due to a short gestation time
and the large number of progeny, their low costs, and the
enhanced microbiological safety made possible by housing
under specified pathogen-free conditions. PERVs are inte-
grated into the genome of all pig strains (Ericsson et al.,
2001; Patience et al., 2001); they are produced by normal
pig cells and can infect human cells (Martin et al., 2000;
Patience et al., 1997; Specke et al., 2001a; Takeuchi et al.,
1998; Wilson et al., 1998, 2000). The replication-competent
PERV-A, PERV-B, and PERV-C are gammaretroviruses
and are closely related to the murine and feline leukemia
viruses able to induce tumors and immunodeficiencies in the
infected host (Denner, 1998). Tumor development by gam-
maretroviruses depends on high levels of replication, inser-
tional mutagenesis, and alterations in the viral long terminal
repeat (LTR) (Athas et al., 1995a). In contrast, the immu-
nopathogenic mechanisms of retroviruses are still unclear,
although the transmembrane envelope proteins of different
retroviruses have been proposed to be involved in this
process (Denner, 2000; Denner et al., 1994). Disrupted
PERVs, their transmembrane envelope protein p15E, and
synthetic peptides corresponding to a highly conserved do-
main of p15E (the so-called immunosuppressive peptides)
have been shown to inhibit human immune cells (Denner,
1998; Tacke et al., 2000) and it is therefore possible that
PERVs may be able to induce immunodeficiency. However,
no PERV infections were observed in initial xenotransplan-
tation patients (Heneine et al., 1998; Paradis et al., 1999;
Tacke et al., 2001) and in numerous in vivo transplantation
and infection experiments using small animals (Specke et
al., 2001b, 2002a) and non-human primates (Denner et al.,
2002; Loss et al., 2001; Specke et al., 2002b; Switzer et al.,
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2001) despite the fact that the cells from most of the species
tested were infected in vitro. Only three publications report
PERV infection of immunodeficient SCID (Deng et al.,
2000; van der Laan et al., 2000) and nude mice (Clem-
enceau et al., 2002).
In order to generate viruses with a higher replication
capacity that could be used in in vivo infection experiments,
PERVs were passaged on human cells. This process also
simulates the situation during xenotransplantation, the re-
lease of PERV from pig cells, and the consecutive infection
of uninfected human cells. Recently we demonstrated that
both pig-cell-derived mixtures of PERV-A and PERV-B
and recombinant viruses with the LTR of PERV-C and the
tropism of PERV-A are able to adapt to human cells and
that this adaptation is associated with an increase in the
length of the LTR (Denner et al., 2001, 2002). In parallel,
molecular clones of PERV-A and PERV-B were passaged
on human cells and an increase in the length of the LTR was
also observed (Krach et al., 2001; Niebert et al., 2002;
Scheef et al., 2001). Here we describe in detail the genetic
changes of a LTR from an ecotropic PERV (PERV-C),
which differs from the LTR of human-tropic PERVs
(PERV-A, PERV-B), during serial passage on and adapta-
tion to human cells, and give an extended characterization
of such human-cell-adapted viruses. We also show that this
adaptation, characterized by increased replication rates, is
not associated with changes in the receptor-binding site.
Results
Comparison of the genetic changes during adaptation of
different PERVs on human cells
As reported previously, serial passage of different
PERVs on human cells resulted in increased virus titers and
enlarged viral LTRs (Denner et al., 2001, 2002). In these
experiments viruses from different sources were used. The
first comprised supernatant from human kidney 293 cells
that had been infected with PERVs from pig PK-15 cells
(Patience et al., 1997) and that produce a mixture of
PERV-A and PERV-B subtypes (PERV/293). The second
virus preparation consisted of supernatant from 293 cells
infected with PERV-NIH/3°, a PERV-A/C recombinant
with the receptor-binding domain of PERV-A and the LTR
of PERV-C generated by passaging virus released from pig
lymphocytes (Wilson et al., 1998, 2000) twice on human
293 cells. Additional passages of both PERV/293 and
PERV-NIH/3° were performed on human 293 cells result-
ing in PERV/4°, PERV/5°, and PERV/6° and PERV/293/I
and PERV/293/II, respectively. After each passage an in-
crease in infectious titer (Table 1) and a decrease in the time
required for the appearance of progeny virus was observed,
indicating an adaptation of PERV to growth on human 293
cells.
Adaptation of retroviruses may be based on changes in
the receptor-binding domain (Taplitz and Coffin, 1997) or
in the long terminal repeat (Athas et al., 1995a, 1995b; Rohn
and Overbaugh, 1995; Stoye et al., 1991). To study the
possible mechanism of adaptation, the env gene (see below)
as well as the whole LTR of integrated proviruses from each
passage, was PCR-amplified, cloned, and sequenced.
PCR and sequence analyses of the LTR regions of
PERVs from different passages showed an increase in the
LTR length (Fig. 1) with multiple insertions of direct re-
peats. The pattern of repeats was different for the two
viruses. In the case of PERV/293 (PERV-A and PERV-B),
the initial sequence comprised 18 bp (TATTTTAAAAT-
GATTGGT) followed by a 21-bp sequence (CCACG-
GAGCGCGGGCTCTCGA) and again the 18-bp sequence
(18 bp–21 bp–18 bp). With each passage the length of the
PERV-A LTR increased by a further 39 bp (21 bp  18 bp)
(Fig. 1) to give 18 bp–21 bp–18 bp–21 bp–18 bp, etc. These
data obtained with pig-cell-derived PERVs confirm previ-
ously reported genetic changes in the LTR when passaging
molecular clones of PERV-A and PERV-B (Scheef et al.,
2001). In contrast, the recombinant virus PERV-NIH/3° (LTR
derived from PERV-C) has a 37-bp sequence (TATTTTGAA-
ATGATTGGTTTGTAAAGCGCGGGCTTTG) in its LTR
that was duplicated with each serial passage (PERV/4° and
PERV/5°). No further increase in the length of the LTR was
observed in PERV/6°. The first 18 bp of this 37-bp sequence
(TATTTTGAAATGATTGGT) are with the exception of
one base identical to the 18-bp sequence in PERV/293
described above (A3G, underlined). Most important, only
one single 21-bp sequence identical to the 21-bp sequence
in PERV-A is located upstream from the 37-bp repeats of
PERV/3°-/5° (Fig. 1). The LTR of PERV-C is therefore
different from that of PERV-A or PERV-B and undergoes
different changes during passage on human cells.
Although the length of the major LTR (the major visible
amplicon in the PCR reaction) increased after each passage
(Fig. 1), proviruses with other LTRs were also present in the
cultures. In the case of PERV/293, LTRs containing be-
tween 1.5 and 5.5 repeats were detected, in the case of
PERV-NIH/3°, PERV/4°, PERV/5°, and PERV/6° LTRs
containing between 1 and 5 repeats were detected. For
comparison, the MSL virus (a PERV-C) found in the pig
genome (Akiyoshi et al., 1998) contains only one such
37-bp sequence. Additionally, a deletion of 26 bp was found
Table 1
The number of repeats correlate with the virus titer
Virus passage Mean number of repeats Titer
PERV/NIH/3° 1 5.3  101
PERV/4° 2 1.1  103
PERV/5° 3a 8.3  103
PERV/6° 2 4.4  103
Note. Equal amounts of RT activity (starting with 27 mU/well) of each
virus passage characterized by different numbers of repeats were used for
titration on human 293 cells.
a Largest number of repeats, 5.
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in some but not all PERV/3° and PERV/5° (Fig. 1). To-
gether, these data clearly demonstrate a sequence multi-
merization in the LTR of the ecotropic PERV-C during
passage on human 293 cells. In addition, the identification
of the U3, R, and U5 regions and the TATA box (ATA-
AAA) in the LTR of the ecotropic PERV-C (Fig. 2) con-
firms the organization of gammaretrovirus LTRs in general
and that of PERV-A and PERV-B LTRs described in part
previously (Scheef et al., 2001).
Promotor activity of LTRs from PERVs serially passaged
on human cells
In the 18-bp repeat sequence of both PERV-A and
PERV-B as well as PERV-C a sequence was identified
which represents a binding site for the nuclear factor Y
(NF-Y) (Denner et al., 2001) giving PERV-NIH/3° two
NF-Y binding sites and PERV/5° six sites.
In addition to the NF-Y binding site, numerous potential
binding sites for other transcription factors were identified
in the PERV-C LTR (Fig. 2). In the 18-bp sequence of
PERV-NIH/3°, PERV/4°, and PERV/5° a binding site spe-
cific for the C enhancer binding protein may be located.
Although it is unclear whether all factors identified bind to
the putative LTR domains and modulate the expression of
PERV, it is striking that no potential binding sites other than
those located inside the repeats changed during passage on
human cells as shown by comparison of the sequence of the
LTRs from PERV-NIH/3° and PERV/5° (Fig. 2). This in-
dicates that the differences in titer were due solely to the
multimerization of the repeat sequences.
To test this assumption, a dual luciferase reporter assay
system was used to investigate the activities of different
LTRs from PERV-C serially passaged on human cells. For
this purpose LTRs with different numbers of repeats were
cloned in front of a luciferase gene. The strength of expres-
sion clearly correlated with the number of repeats (Fig. 3).
These data show that in contrast to PERV-A and
PERV-B (Fig. 1) (Scheef et al., 2001) different repeats were
multiplied in the LTR of PERV-C, but that in all viruses
NFY-bindings sites were multiplied. These multiplications
correlated in both cases with the expression of reporter
genes (Fig. 3) (Scheef et al., 2001).
In order to analyze whether multiplications of LTR re-
peat boxes also correlate with virus replication, equal
amounts of virus (as measured by RT) of different passages
were titrated on human 293 cells and an increase in the titer
was observed correlating with the number of passage (Table
Fig. 1. Differences in the organization of the LTR from PERV-A and PERV-C and differences in the genetic changes during the passage of both viruses on
human 293 cells. A: LTRs from PERV originally derived from PK-15 cells (PERV-A and PERV-B); B: LTRs from a recombinant PERV-A/C, originally
derived from pig lymphocytes. The length of the amplicon obtained after amplification using primers described under Methods is indicated; the black boxes
indicate sequences outside the repeats; the sequence of the other boxes is given. The 18-bp sequence is with the exception of 1 bp (underlined) identical in
both virus types. In the PERV-C LTR only one 21-bp sequence was found.
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1). Therefore, we showed for the first time that the number
of repeats correlated not only with the expression of reporter
genes but also with the replication of the virus.
Absence of changes in the env gene of PERVs serially
passaged on human cells
To test whether the increased virus titer could be due to
changes in receptor usage, the entire env genes (coding for
the surface envelope protein gp70) of PERV-NIH/3° and
PERV/5° were cloned and sequenced. No mutations were
observed in the receptor binding sites after passaging the
virus on human cells (Fig. 4), indicating that the main factor
involved in adaptation to human cells was the genetic al-
teration in the LTR.
PERV/5° but not PERV/293 or PERV-NIH/3° infects a
human T cell line
In order to study whether similar changes in the LTR can
be observed when PERVs were passaged on other human
cells, the human T cell line C8166 was infected with PERV/
293, PERV-NIH/3°, and PERV/5°. Since this cell line could
not be infected with PERV/293 and PERV-NIH/3°, pas-
sages could not be performed. However, PERV/5° was able
to infect C8166 cells (Fig. 5), indicating that the increased
Fig. 2. Comparison of the organization of LTRs of an early passage (PERV-NIH/3°) with one repeat and a later passage (PERV/5°) with five repeats. The
repeats are framed in black, the R region in green, and the U5 in blue and the U3 region is not framed. The TATA box (ATAAAA) and the polyadenylation
site (AATAAAAA) are shown in a solid black box and putative binding sites for NF-AT in gray (GAAA), for Oct-1 in blue (ATGC), for Ets-1 in green
(AGGA), for CEBP in magenta (GAAA), for v-myb in dark blue (AACG), for HFH-3 in green (TGTT), for NF-1 in olive (TGGC), for AP-1 FJ in light blue
(TGACAACA), for NF-Y in red (ATTGG), and for AP-1 C in brown (GTGAGTGAT) boxes.
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replication competence leads to successful infection. When
passaging this virus on C8166 cells, a de novo infection was
observed, but as in the case of PERV/5° on 293 cells no
further increase in the LTR length was observed (Fig. 5).
These data also indicate that human lymphoid cell lines can
be infected productively with PERV.
Discussion
The results of this study indicate that serial passage of
PERV on human cells led to an adaptation of the virus
associated with shorter infection times, higher virus produc-
tion, higher infectious titres, reduced number of defective
particles, and increased LTR length. Since expression as-
says using reporter genes showed that the repeat motif
enhances the activity of retroviral promoters in our (Fig. 4)
and other retroviral systems (Athas et al., 1995b; Scheef et
al., 2001), we propose that the genetic changes in the LTR
are the molecular basis for the adaptation observed. In the
genome of German landrace pigs and Yucatan micropigs,
proviruses carrying PERV-C LTRs with five 37-bp repeats
could not be detected using nested PCR (unpublished data).
To discriminate between PERVs present in the pig genome
and viruses characterized by multiple repeats and PERV-A/
PERV-C recombinations generated during infection of and
growth on human cells the term “human-adapted PERVs”
(HAPs) should be used.
Fig. 3. Promotor activity of LTRs with different numbers of repeats (compare Fig. 1) using a dual luciferase reporter assay. The activity was measured on
human 293 cells, LTRs from early (PERV-NIH/3°) and later passages (PERV/5°) were used, and the relative light units (RLU) were measured as described
under Methods.
Fig. 4. Sequence comparison of env sequences from an early (PERV-NIH/3°) and a later passage (PERV/5°). The mutated amino acids (aa 231, 415) are
underlined; the localization of the virus receptor binding sites A and B is shown (VRA, VRB).
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The multiplication of enhancer sequences may have se-
rious implications for the infectivity and pathogenicity of
these viruses as they provide signals not only for the tran-
scription of viral genes but also for the transcription of
cellular genes after integration of the provirus. Lymphoma
induction in mice and cats appears to be dependent on the
generation of viruses containing duplicated enhancer se-
quences (DesGrosseillers and Jolicoeur, 1984; Stoye et al.,
1991; Athas et al., 1995a, 1995b). Viruses with duplicated
enhancers were found in animals that died of thymic lym-
phoma, but not in healthy animals and these viruses were
generated and selected after only a single passage in cats
(Rohn and Overbaugh, 1995).
Multimerization of enhancer repeats were described not
only for exogenous retroviruses, but also for endogenous
viruses. Mouse endogenous retroviruses unable to replicate
under normal conditions were able to replicate after hor-
mone treatment due to a multimerization of LTR sequences
(Wolgamot and Miller, 1999). To summarize, multimeriza-
tion of enhancer sequences as observed in PERVs passaged
on human cells was associated in other retroviral systems
with increased tumorigenicity. These data demonstrate the
potential capacity of PERVs for increased replication in
human tissues that could be associated with both tumorige-
nicity (higher probability of insertion mutagenesis) and pro-
gression to immunodeficiency as described for other retro-
viruses (Pantaleo et al., 1993). The dual luciferase reporter
assays demonstrated that the number of repeats in human-
adapted PERVs carrying a LTR specific for PERV-C clearly
correlates with the expression of the reporter gene (Fig. 3).
Similar results were obtained when molecular clones of
PERV-A and PERV-B were passaged on human 293 cells
(Scheef et al., 2001). Since no genetic changes were de-
scribed for the other parts of the LTR and the gene encoding
the surface envelope protein, it is likely that the increase in
virus titer is due to the multimerization of the repeats. The
largest LTR with five 37-bp repeats was observed after five
passages of the PERV-C (PERV/5°) (Fig. 1). Further rounds
of passaging PERV/5° on human 293 cells did not increase
the number of repeats further (Fig. 1), indicating that the
copy number is balanced by the natural instability of retro-
viral repeats and constraints imposed by virion packaging
limits. This explains also why further passaging of PERV/5°
on the human lymphoid T cell line C8166 was not associ-
ated with increased titers and larger LTRs (Fig. 5).
In total these data demonstrate a complex scenario of
adaptive changes after infection of human cells by pig
derived PERVs. First, when PERV-A, PERV-B, and
PERV-C were released from pig cells (Tacke et al., 2003),
recombinations between PERV-A and PERV-C were ob-
served (Wilson et al., 1998, 2000), allowing previously
ecotropic viruses to replicate on human cells. Second, the
LTRs of polytropic (PERV-A, PERV-B) and recombinant
ecotropic (PERV-A/C), all able to infect human cells, in-
crease in length during passages on human cells. Although
not yet described, these events may also occur in vivo
during experimental or clinical xenotransplantation, with a
pig virus released from the xenotransplant infecting and
adapting to human cells. However, in vivo transmission of
PERV has been observed neither in first clinical xenotrans-
plantations with pig islet cells or skin nor during ex vivo
perfusion treatment (Cunningham et al., 2001; Paradis et al.,
1999; Tacke et al., 2001; Sauer et al., 2003; Irgang et al.,
2003). Furthermore, no transmission of PERV was observed
in butchers having blood–blood contact with pigs (Tacke et
al., 2001) or in experimental xenotransplantations with rats
and monkeys using organs, cells, or cell-free PERVs and
HAPs (Denner et al., 2001; Loss et al., 2001; Switzer et al.,
2001). Even in monkeys undergoing triple immunosuppres-
sive therapy (to simulate the conditions during xenotrans-
plantation) and despite in vitro data showing the suscepti-
bility of the primate cells to PERV infection, no in vivo
infection was observed (Denner et al., 2002; Specke et al.,
2002b). The extensive genetic, biochemical, and morpho-
logical characterization of the human-adapted PERVs being
used in several in vitro and in vivo infection experiments is
crucial to allow the future evaluation of experimental and
clinical xenotransplantations.
Methods
Viruses
Two sources of virus were used for adaptation experi-
ments: (i) PERV-A and PERV-B (designated PERV/293)
produced by human 293 kidney cells (Patience et al., 1997;
kindly provided by R. Weiss, Wohl Virion Center, London,
UK), and (ii) PERV-NIH, third passage (designated PERV-
NIH/3°, Wilson et al., 1998), also produced by human 293
cells (kindly provided by C. Wilson, FDA, Washington,
Fig. 5. A: Provirus integration (PERV/C8166/7°) in cells of the human T
cell line C8166 after infection with a virus derived from C8166 cells. The
virus used for infection, PERV/C8166/6°, was produced by C8166 cells
after infection with PERV/5°. For the detection of the provirus primers for
gag (1), pol (2), envA (3), envB (4), and -actin (5) were used. B:
Comparison of the LTR lengths of PERV/C8166/6° (1) and PERV/
C8166/7° (2). M, marker.
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DC, USA). PERV-NIH/3° has been shown to be a recom-
bination between PERV-A and PERV-C and can infect
different human cells (Wilson et al., 2000).
Virus passage
To obtain higher passages, uninfected human kidney 293
cells were inoculated with PERV/293 or PERV-NIH/3° for
24 h in the presence of 8 g/ml polybrene (Sigma, Deisen-
hofen, Germany). Cells were cultivated and viruses were
serially passaged as soon as a new virus generation (PERV/
293/I and PERV/293/II and PERV/4°, PERV/5°, and
PERV/6°, respectively) was observed. Virus production was
monitored by measuring RT activity in the supernatant and
by titration. In parallel, a human T cell line, C8166, was
used in infection experiments with PERV/293, PERV-NIH/
3°, and PERV/5°. After successful infection with PERV/5°,
this virus was passaged again on C8166 to obtain PERV/
6°/C8166.
Virus titration
Virus-containing supernatant produced by a confluent
PERV-producing cell culture (1  107 293 cells) was taken
3 days after the last medium change. Cells were removed by
centrifugation and sterile filtration. The supernatant was
serially diluted (eight replicates per dilution) before transfer
to 96-well plates containing uninfected 293 cells (3 
104/well) and incubation at 37°C with 5% CO2 and 98%
humidity. On the following day cells were washed with PBS
and cultured for 4 weeks, splitting the cells using trypsin
every 3–4 days after washing with PBS. Every 7 days a
sample of the cells was screened by immunoperoxidase
assay for virus expression using a PERV p15E specific
antiserum (Stephan et al., 2001). Briefly, cells were seeded
in 96-well plates (3  104 cells/well) coated with poly-D-
lysine (Greiner, Germany), washed twice with PBS, and
fixed with methanol overnight at 20°C. Cells were treated
with 2% fat-free milk powder (w/v) (Marvel, UK) in PBS
for 1 h to block nonspecific antibody binding. Thereafter the
cells were incubated for 1 h with an antiserum against
recombinant PERV p15E (diluted 1:100 in blocking solu-
tion). After being washed four times with PBS, cells were
incubated with horseradish peroxidase labeled protein G
(1:5000) for 1 h and washed again four times with PBS. The
substrate solution (containing 4 mg 3-amino-9-ethylcarba-
zole dissolved in 1 ml dimethylformamide and 19 ml 20
mM sodium acetate buffer, pH 5.2, and 20 l H2O2) was
added.
PCR and cloning of PERV LTRs
The primers AAAGGATGAAAATGCAACCTAACC
and ACGCACAAGACAAAGACACACGAA (Czauderna
et al., 2000) were used for direct amplification of a PERV 5
LTR sequence. Amplification was carried out using stan-
dard PCR conditions in a Biozym cycler (Biozym Diagnos-
tic, Oldendorf, Germany): one initial cycle of 10-min dena-
turation at 95°C, 35 cycles of 1-min denaturation at 95°C,
1-min annealing at 58°C, 1-min elongation at 72°C, and one
final cycle of 7-min elongation at 72°C. The amplicons were
cloned into a pCR2.1-TOPO vector (Invitrogen). DNAstar
MegAlign was used for homology comparison and Matin-
spector (Genomatix) for identification of factor binding
sites.
Dual luciferase reporter assay
To analyze differences in LTR expression, the dual lu-
ciferase reporter assay was used (Promega). LTRs were
cloned into the pGL3 vector carrying the firefly luciferase.
pRL-TK carrying the renilla luciferase was used to control
the transfection efficiency. Transfected human 293 kidney
cells were washed with PBS and lysed at room temperature
with 100 l of lysis puffer (Promega) after 48 h. The
luciferase assay was performed with a WinGlow 1.24 lu-
minometer (Berthold). Each measurement was carried out
using 20 l cell lysate after addition of 100 l LAR II and
100 l Stop and Glo (Promega), respectively. For each
vector three separate transfection experiments were per-
formed and measurement was carried out in six replicates.
Relative light units were defined as the mean values of the
luciferase activity divided by the mean values of the renilla
activity.
PCR and cloning of PERV env
DNA from PERV/5° producing cells was extracted using
the QIAamp DNA MiniKit (Qiagen). The env gene was
amplified using specific primers (TTATGAGCTCATG-
CATCCCACGTTAAGCC and CCCAACTGCAGTCTT-
TTTGGCCGATTATATCT). The PCR product was puri-
fied, digested with the restriction enzymes SacI and PstI,
and cloned into the vector pQE30 (Qiagen). The sequence
of the insert was determined by DNA sequence analysis
(Medigenomix).
RT assay
A commercial reverse transcriptase assay (Cavidi Tech,
Uppsala, Sweden) was used to detect productive PERV
infection of target cells.
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